Nicole Forestier

Summary

Affiliation: Saarland University
Country: Germany

Publications

  1. ncbi Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Nicole Forestier
    Saarland University Hospital, Homburg, Germany
    Hepatology 46:640-8. 2007
  2. ncbi Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
  3. ncbi SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders
    Christoph Sarrazin
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:1270-8. 2007
  4. ncbi Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease
    Tanja M Raedle-Hurst
    Second Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 20:865-73. 2008
  5. ncbi Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study
    Hendrik W Reesink
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Gastroenterology 131:997-1002. 2006
  6. ncbi Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
    Tara L Kieffer
    Vertex Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Hepatology 46:631-9. 2007
  7. ncbi Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
    Huub C Gelderblom
    Department of Gastroenterology and Hepatology, AMC Liver Center, Homburg Saar, Germany
    Scand J Gastroenterol 43:1122-7. 2008
  8. ncbi Novel hepatitis C drugs in current trials
    Bernd Kronenberger
    Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Clin Liver Dis 12:529-55, viii. 2008

Detail Information

Publications8

  1. ncbi Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Nicole Forestier
    Saarland University Hospital, Homburg, Germany
    Hepatology 46:640-8. 2007
    ..CONCLUSION: This study confirmed the substantial antiviral effects of telaprevir and showed an increased antiviral effect of telaprevir combined with peginterferon alfa-2a...
  2. ncbi Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection
    Mireen Friedrich Rust
    Department of Internal Medicine, Saarland University Hospital, Homburg Saar, Germany
    Ultrasound Med Biol 33:1362-7. 2007
    ....
  3. ncbi SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders
    Christoph Sarrazin
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:1270-8. 2007
    ....
  4. ncbi Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease
    Tanja M Raedle-Hurst
    Second Department of Medicine, Saarland University Hospital, Homburg Saar, Germany
    Eur J Gastroenterol Hepatol 20:865-73. 2008
    ..The aim of the study was to validate the N-terminal propeptide of the brain natriuretic peptide (NT-proBNP) in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease...
  5. ncbi Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study
    Hendrik W Reesink
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Gastroenterology 131:997-1002. 2006
    ..4A protease of hepatitis C and has antiviral activity in vitro. This phase I, placebo-controlled, double-blind study evaluated the antiviral activity, pharmacokinetics, and safety of VX-950 in patients with chronic hepatitis C (CHC)...
  6. ncbi Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
    Tara L Kieffer
    Vertex Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Hepatology 46:631-9. 2007
    ....
  7. ncbi Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a
    Huub C Gelderblom
    Department of Gastroenterology and Hepatology, AMC Liver Center, Homburg Saar, Germany
    Scand J Gastroenterol 43:1122-7. 2008
    ..4A protease inhibitor telaprevir (VX-950), with or without peginterferon alfa-2a (Peg-IFN)...
  8. ncbi Novel hepatitis C drugs in current trials
    Bernd Kronenberger
    Zentrum der Inneren Medizin, Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Clin Liver Dis 12:529-55, viii. 2008
    ....